GlassScriptPhysician profile
Nikita Jain
NPI 1801381900
$8,390.02
in general payments reported to CMS, 2019-2025
50 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,012 · 2022: $2,178 · 2023: $2,454 · 2024: $2,014 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,918.47 |
| Education | $281.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $679.56 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $541.21 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $525.89 | 2021-2024 | Opdivo, Opdualag, Reblozyl |
| Incyte Corporation | $516.38 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $514.70 | 2021-2023 | Lumakras, Kyprolis, Vectibix |
| Seagen INC. | $480.99 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $399.58 | 2021-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $353.52 | 2021-2024 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $286.92 | 2022-2025 | Erleada, Talvey, Tecvayli |
| Abbvie INC. | $274.99 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $251.43 | 2021-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $241.26 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $201.30 | 2023-2025 | Keytruda, Lynparza |
| Eisai INC. | $198.31 | 2021-2025 | |
| Adc Therapeutics America, INC. | $194.78 | 2023-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.29 | 2021-2025 | Imfinzi, Lynparza, Tagrisso |
| Astellas Pharma US INC | $182.40 | 2025 | |
| Adaptive Biotechnologies Corporation | $179.41 | 2022-2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $168.93 | 2021-2024 | |
| Pfizer INC. | $158.11 | 2022-2024 | |
| Mirati Therapeutics, INC. | $157.21 | 2023-2024 | Krazati |
| Emd Serono, INC. | $145.87 | 2021-2022 | |
| Sobi, INC | $139.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.39 | 2022-2024 | Libtayo |
| Sirtex Medical INC | $128.01 | 2023 | Sir-Spheres Microspheres |
| Stemline Therapeutics INC. | $103.18 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Exelixis INC. | $91.22 | 2024 | Cabometyx |
| Beigene USA, INC. | $90.02 | 2021-2023 | Brukinsa |
| Jazz Pharmaceuticals INC. | $82.51 | 2024-2025 | |
| Celgene Corporation | $75.76 | 2024-2025 | Reblozyl, Opdualag, Onureg |
| Coherus Oncology, INC. | $64.89 | 2022-2025 | Loqtorzi, Udenyca |
| Ipsen Biopharmaceuticals, INC | $61.90 | 2021-2023 | Tazverik |
| Sumitomo Pharma America, INC. | $48.27 | 2023-2025 | Orgovyx |
| Array Biopharma INC | $45.85 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacosmos Therapeutics INC. | $45.21 | 2024 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.74 | 2021 | |
| Genentech USA, INC. | $36.68 | 2022 | |
| Puma Biotechnology, INC. | $34.32 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $29.60 | 2025 | Ultomiris |
| Pharmaessentia USA Corporation | $27.31 | 2024 | Besremi |
| Lilly USA, LLC | $24.57 | 2024 | Retevmo, Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $20.87 | 2023 | Ojjaara |
| Dova Pharmaceuticals | $19.54 | 2021 | |
| Cti Biopharma Corp. | $19.25 | 2022 | |
| Kyowa Kirin, INC. | $18.66 | 2023 | Poteligeo |
| Medtronic, INC. | $16.74 | 2024 | Synchromedii |
| Azurity Pharmaceuticals, INC. | $16.65 | 2023 | Gliadel |
| Takeda Pharmaceuticals U.S.A., INC. | $15.85 | 2025 | Fruzaqla |
| Apellis Pharmaceuticals, INC. | $15.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikita Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.